Cost Is a Major Barrier to Besremi Adherence

Besremi (Ropeginterferon Alfa-2b) is a breakthrough treatment for polycythemia vera — the only FDA-approved interferon specifically designed for PV. But at $9,700 to $11,000 per injection, its price tag creates a real barrier for many patients. Even with insurance, copays for specialty biologics can reach hundreds or thousands of dollars per month.

As a prescriber, you know that the best treatment plan fails if patients can't afford to stay on it. Medication non-adherence due to cost isn't just a financial problem — it's a clinical one. Patients who skip doses or abandon Besremi treatment lose the disease-modifying benefits that make interferon therapy uniquely valuable for PV.

This guide provides a practical framework for helping your patients access every available savings option and building cost conversations into your PV management workflow.

What Your Patients Are Actually Paying

Understanding the landscape helps you anticipate which patients will struggle:

Commercially Insured Patients

Most commercial plans cover Besremi after prior authorization. However, specialty tier copays can range from $100 to $3,000+ per month depending on the plan design. High-deductible health plans (HDHPs) are particularly challenging — patients may face full cost until they hit their deductible.

Medicare Patients

Medicare Part B may cover Besremi under the medical benefit (buy-and-bill), while Part D covers it as a specialty pharmacy benefit. Under Part D, patients in the coverage gap ("donut hole") can face significant out-of-pocket costs. The Inflation Reduction Act's $2,000 annual out-of-pocket cap (effective 2025) helps, but patients still need assistance navigating the coverage landscape.

Medicaid Patients

Medicaid generally covers Besremi with prior authorization, and out-of-pocket costs are minimal. The main challenge for Medicaid patients is navigating the prior authorization process and specialty pharmacy requirements.

Uninsured Patients

Without any coverage, Besremi's annual cost exceeds $250,000. These patients need immediate enrollment in patient assistance programs.

Manufacturer Savings Programs

PharmaEssentia operates a comprehensive patient support platform called SOURCE that should be your first recommendation for every Besremi patient.

SOURCE Copay Assistance Program

• Eligibility: Commercially insured patients
• Benefit: Reduces out-of-pocket cost to as little as $0 per month
• Covers: Copay, coinsurance, and deductible expenses for Besremi
• Enrollment: BESREMiCopay.com or through the SOURCE program
• Exclusions: Patients on federal or state programs (Medicare, Medicaid, TRICARE, VA) are not eligible for copay assistance due to federal anti-kickback regulations

This is the single most impactful intervention for commercially insured patients. Enrollment is straightforward, and your office staff can initiate it at the time of prescribing.

SOURCE Patient Assistance Program (PAP)

• Eligibility: Uninsured or underinsured patients who meet financial criteria
• Benefit: Provides Besremi at no cost
• Enrollment: Call 1-833-546-7473
• Processing: Requires income verification and documentation of insurance status

For uninsured patients, this program is essential. The SOURCE team handles most of the administrative work, but a prescription from your office is required to initiate the process.

SOURCE Hub Services

Beyond financial assistance, SOURCE provides:

• Prior authorization support and appeals assistance
• Benefits verification
• Specialty pharmacy coordination
• Nurse educators for patient injection training
• Ongoing case management

Connecting your patients with SOURCE at the point of prescribing eliminates many downstream barriers.

Coupon and Discount Cards

For a specialty biologic like Besremi, traditional coupon cards (GoodRx, SingleCare, etc.) offer limited value. Here's why:

• Besremi is only available through specialty pharmacies, not retail pharmacies where most discount cards work
• The cash price is so high that percentage discounts still leave enormous out-of-pocket costs
• The manufacturer copay assistance program typically provides far greater savings than any third-party coupon

That said, patients may occasionally find value in:

• GoodRx — Can show specialty pharmacy pricing and occasionally offers savings on specialty medications
• RxAssist and NeedyMeds — Databases of patient assistance programs that may help patients identify additional resources

In practice, the PharmaEssentia SOURCE programs should be exhausted before exploring third-party options.

Generic Alternatives and Therapeutic Substitution

There is currently no generic version of Besremi available. However, understanding the therapeutic landscape helps when cost is a deciding factor in treatment selection.

When Besremi Is the Optimal Choice

• Patients who are candidates for interferon therapy and want an FDA-approved, PV-specific option
• Patients transitioning from Pegasys (currently in shortage)
• Patients who prefer every-two-week dosing over weekly interferon
• Younger patients where disease modification and JAK2 allele burden reduction are priorities

When Cost Drives Therapeutic Alternatives

If a patient truly cannot access Besremi financially despite all assistance programs, consider:

• Hydroxyurea (Hydrea, Droxia) — The most commonly used first-line cytoreductive therapy for PV. Generic Hydroxyurea costs $50-$200 per month, making it highly accessible. It's effective for blood count control but doesn't reduce JAK2 allele burden and carries a small long-term leukemia risk.
• Ruxolitinib (Jakafi) — An oral JAK inhibitor approved for PV patients with inadequate response to or intolerance of Hydroxyurea. Also a high-cost specialty medication (~$15,000-$17,000/month), but Incyte offers its own copay and patient assistance programs.

For a full comparison of alternatives, see our PV treatment alternatives guide.

Building Cost Conversations into Your Workflow

Cost discussions shouldn't be an afterthought. Here's how to integrate them into your PV management workflow:

At the Point of Prescribing

1. Assess insurance status — Commercial, Medicare, Medicaid, or uninsured? This determines which programs are available.
2. Initiate SOURCE enrollment — Have your staff connect the patient with PharmaEssentia SOURCE before the prior authorization even goes through. This runs in parallel and avoids delays.
3. Set expectations — Tell patients that Besremi is an expensive medication but that assistance programs exist. Most commercially insured patients will pay little to nothing out of pocket with copay assistance.
4. Document the conversation — Note in the chart that cost was discussed and which assistance programs were recommended.

During Treatment

• Check in on affordability at regular visits — Insurance changes, job changes, and life events can affect a patient's ability to afford treatment.
• Monitor for non-adherence — If blood counts are worsening or a patient is requesting fewer refills, cost may be the reason. Ask directly.
• Renew assistance programs — Most copay assistance programs need annual renewal. Build reminders into your workflow.

When Insurance Changes

Job changes, open enrollment, aging into Medicare — any insurance transition can disrupt Besremi access. When you learn of a change:

• Re-verify benefits immediately
• Submit new prior authorization if needed
• Update assistance program enrollment (commercially insured → Medicare requires transitioning from copay assistance to PAP or other resources)
• Consider bridge supplies through SOURCE to prevent treatment gaps

Staff Training

Your front-desk and prior authorization staff are critical partners in this process. Ensure they know:

• How to connect patients with PharmaEssentia SOURCE (1-833-546-7473)
• The difference between copay assistance (commercial) and patient assistance (uninsured/underinsured)
• How to initiate prior authorization for Besremi
• When to escalate appeals for denials

Additional Resources for Your Practice

• PharmaEssentia SOURCE: 1-833-546-7473 | BESREMiCopay.com
• NCCN Guidelines for MPN: Updated January 2025, now includes Besremi as Category 1 preferred for PV
• MPN Research Foundation: Patient education resources you can share
• Medfinder for Providers: Help patients locate specialty pharmacies with Besremi in stock

Final Thoughts

Besremi's clinical profile makes it a compelling choice for PV management — disease-modifying potential, convenient dosing, and the only FDA-approved interferon for the indication. But none of that matters if patients can't afford to stay on treatment.

The infrastructure exists to make Besremi accessible to most patients. The PharmaEssentia SOURCE Copay Assistance Program covers most commercially insured patients at $0 per month. The Patient Assistance Program serves uninsured patients at no cost. Your role as a provider is to connect patients with these resources proactively, not reactively.

Make cost conversations standard practice. Initiate assistance enrollment at the point of prescribing. Monitor for non-adherence signals. And train your staff to be part of the solution. When financial barriers are addressed upfront, patients can focus on what matters — getting better.

For more provider resources, visit Medfinder for Providers.